Free Trial

Agile Therapeutics Q4 2022 Earnings Report

Agile Therapeutics EPS Results

Actual EPS
-$9.00
Consensus EPS
-$10.50
Beat/Miss
Beat by +$1.50
One Year Ago EPS
N/A

Agile Therapeutics Revenue Results

Actual Revenue
$4.00 million
Expected Revenue
$3.17 million
Beat/Miss
Beat by +$830.00 thousand
YoY Revenue Growth
N/A

Agile Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Agile Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Agile Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agile Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agile Therapeutics and other key companies, straight to your email.

About Agile Therapeutics

Agile Therapeutics (NASDAQ:AGRX), a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

View Agile Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings